San Francisco, CA, United States of America

Mark J Selby

USPTO Granted Patents = 87 

 

 

Average Co-Inventor Count = 5.1

ph-index = 18

Forward Citations = 3,009(Granted Patents)

Forward Citations (Not Self Cited) = 2,714(Dec 10, 2025)


Inventors with similar research interests:


Location History:

  • Emeryville, CA (US) (2008)
  • San Franciso, CA (US) (2008)
  • San Francisco, CA (US) (1999 - 2023)

Company Filing History:


Years Active: 1999-2025

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Antibodies Binding to ILT4
Anti-CD27 Antibodies
Anti-GITR Antibodies
Human Monoclonal Antibodies
Lymphocyte Activation Gene-3
TIM3 Antibodies
Ipilimumab Variant
Anti-ICOS Agonist Antibodies
Combination Therapies
Cancer Diagnostics
PD-1 Antibodies
Tumor Treatment
87 patents (USPTO):Explore Patents

Title: Mark J. Selby: Pioneering Innovations in Cancer Treatment

Introduction

Mark J. Selby is a distinguished inventor based in San Francisco, CA, recognized for his substantial contributions to the field of cancer therapy. With an impressive portfolio of 85 patents, Selby has consistently been at the forefront of medical innovations that aim to improve patient outcomes in oncology.

Latest Patents

Among his most recent patents are significant advancements in the treatment of cancer. One such patent is for the combination of TIM-4 antagonist and PD-1 antagonist, providing methods and compositions for effectively treating cancer using these agents. This innovation highlights his focus on harnessing the immune system to fight cancer.

Additionally, Selby has developed antibodies against TIM3, detailing the uses of these antibodies in therapeutic applications for cancer treatment. His innovations extend to the creation of cells that produce these antibodies, along with the associated polynucleotides and vectors necessary for their production, showcasing his comprehensive approach to biomedical research.

Career Highlights

Throughout his career, Selby has made significant contributions while working with notable companies such as Bristol-Myers Squibb Company and E.R. Squibb & Sons, L.L.C. His work at these leading pharmaceutical firms has helped shape the landscape of cancer treatment and biotherapeutics.

Collaborations

Mark Selby has collaborated with esteemed colleagues in the industry, including Alan J. Korman and Mohan Srinivasan. These partnerships have further enhanced his research and innovation efforts, leading to the development of cutting-edge therapies that benefit patients worldwide.

Conclusion

Mark J. Selby stands out as a prominent inventor in the realm of cancer research, with his extensive patent portfolio reflecting his dedication to medical advancements. His groundbreaking work in combining immune therapies and developing novel antibodies serves as an inspiration for future innovations in the fight against cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…